Natural killer cells that live in the lungs can rapidly respond to a sugar rush, making them especially effective

published today in the journal Proceedings of the National Academy of Sciences, provide a foundation for further exploration of NK cells for the development of future treatments and therapies for a range of lung diseases, including chronic obstructive pulmonary disease (COPD), cancer and tuberculosis.

The human lung is normally a low glucose environment. During infection, however, glucose becomes readily available and its rapid uptake and metabolism enables immune cells to fight off infections. Natural killer (NK) cells are immune cells tasked with mediating early host defense. The NK cells that live long-term in the lung, or in other organs, are called tissue-resident. Before this study, the metabolic function of human tissue-resident NK cells in the lung was largely unknown.

Researchers have shown for the first time that human tissue-resident NK cells in the lung are metabolically distinct from their counterparts that circulate in the blood. The team’s findings show that lung-resident NK cells are poised to rapidly respond to increased glucose in the environment, with an enhanced capacity to increase the metabolism of glucose in order to generate materials that the NK cells need to mount an effective immune response.

Key findings include:

• Metabolic distinction: Lung tissue-resident NK cells are metabolically distinct from their counterparts in the blood, showing a unique capacity to rapidly metabolize glucose in response to environmental changes, such as during infections.
• Enhanced glycolytic capacity: These lung-resident NK cells exhibit a higher glycolytic capacity compared to non-tissue-resident NK cells. This allows them to generate energy and necessary metabolites more efficiently, enabling a swift immune response.
• Primed for response: The metabolic readiness of lung-resident NK cells indicates they are primed to respond quickly to increased glucose availability during infections, enhancing their ability to mount an effective immune defense.
• Implications for disease: Understanding the distinct metabolic profile of lung-resident NK cells opens new avenues for investigating dysfunctional NK cells in respiratory diseases, suggesting that metabolism could be a target for immuno-supportive therapies in conditions like cancer and chronic infections.

Researchers noted one surprising aspect to their findings, in the readiness of the lung-resident cells to switch on their glycolytic pathways even before an infection occurs, almost as if they are primed and waiting for a sugar rush to activate them. This metabolic readiness highlights a specialized adaptation of the lung NK cells that makes them particularly effective in their local environment, which could be a key target for future therapies in lung diseases, including cancer and infections.

Lead author on the paper Dr. Gráinne Jameson describes her work, saying, “These findings are exciting because they establish that the NK cells in the lung are metabolically different to the NK cells found in blood. This is impactful because it will enable the investigation of dysfunctional NK cells in respiratory diseases and shows that the metabolism of lung resident NKs is a tractable target for inhalable therapies for many settings of lung disease, including cancer and infection. “

Assistant Professor Sharee Basdeo in the department of clinical medicine and senior author on the paper, said, “This work has used a cutting-edge technique to establish the metabolic function of these NK cells taken from clinical samples of lung washings. This allowed us to define for the first time how these cells that live in the lung use energy sources. These findings will enable future studies which will support the function of lung resident NK cells to better fight infections.”